Titre officiel
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Sommaire:
Cet essai de phase II/III à répartition aléatoire
étudie le fonctionnement de la radiothérapie lorsqu'elle est combinée au
cisplatine comparativement au docétaxel ou au cetuximab et docétaxel après une
chirurgie pour traiter les patients atteints d'un épithélioma malpighien
spinocellulaire de la tête et du cou de stade III et IV. Une radiothérapie
spécialisée qui délivre une forte dose de rayonnement directement sur la tumeur
pourrait détruire un plus grand nombre de cellules tumorales et moins léser les
tissus normaux. Les médicaments utilisés en chimiothérapie, comme le cisplatine
et le docétaxel, bloquent la croissance des cellules cancéreuses de différentes
manières, soit en tuant les cellules, soit en les empêchant de se diviser. Les
anticorps monoclonaux, comme le cetuximab, peuvent arrêter la croissance des
tumeurs de diverses façons. Certains bloquent la capacité des cellules
tumorales à grossir et à s'étendre. D'autres trouvent les cellules tumorales et
contribuent à les éliminer ou à leur transmettre les molécules qui tuent les
tumeurs. On ne sait pas encore si la radiothérapie est plus efficace
lorsqu'elle est combinée au cisplatine, au docétaxel, ou au cetuximab et au
docétaxel.
Description de l'essai
Primary Outcome:
- Disease-free survival (DFS) (Phase II)
- Overall survival (OS) (Phase III)
Secondary Outcome:
- Local-regional failure (LRF)
- Distant metastasis (DM)
- Toxicity
- Patient-reported outcome, symptom burden
- Quality of life
PRIMARY OBJECTIVES:
-
To select the better docetaxel-based experimental arm to improve disease-free survival
(DFS) over the control arm of radiation and cisplatin. (Phase II) (COMPLETE AS OF
20-MAR-2020)
- To determine if the combination of docetaxel-cetuximab and
intensity-modulated radiation therapy (IMRT) is superior in terms of overall survival (OS)
compared to standard cisplatin and IMRT in the adjuvant treatment of pathologic high risk,
human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC). (Phase
III)
- To determine if the combination of atezolizumab, cisplatin, and IMRT is superior in
terms of OS compared to standard cisplatin and IMRT in the adjuvant treatment of pathologic
high risk, HPV-negative HNSCC. (Phase III)
SECONDARY OBJECTIVES:
-
To compare disease-free survival (DFS) between each experimental arm and the control arm.
(Phase III)
- To determine whether each experimental arm improves local-regional disease
control and the rate of distant metastasis. (Phase III)
- To compare acute toxicity
profiles between each experimental arm and the control arm. (Phase III)
- To compare late
toxicity profiles at 1, 3, and 5 years after treatment. (Phase III)
- To assess long term
DFS and OS between each experimental arm and the control arm. (Phase III)
- To compare
symptom burden, as measured by the MD Anderson Symptom Inventory - Head and Neck (MDASI-HN)
(primary patient reported outcome [PRO]), and quality of life, as measured by the Functional
Assessment of Cancer Therapy - Head and Neck (FACT-H&N) (secondary PRO), between each
experimental arm and the control arm. (Phase III)
EXPLORATORY OBJECTIVE:
-
To collect blood and tissue specimens for future translational research. (Phase III)
OUTLINE:
Patients are randomized to 1 of 3 arms - Phase II (Arms 1, 2 or 3) and for Phase III
(Arms 1, 3 or 4).
ARM 1: Patients undergo intensity modulated radiation therapy (IMRT) once daily (QD) five
days a week for 6 weeks and receive concurrent cisplatin intravenously (IV) over 1-2 hours
once weekly for 6 weeks.
ARM 2: Patients undergo IMRT as in Arm I and receive concurrent docetaxel IV over 60 minutes
once weekly for 6 weeks. (CLOSED AS OF 20-MAR-2020)
ARM 3: Patients receive cetuximab IV over 120 minutes on week 1 and over 60 minutes once
weekly on weeks 2-7. Patients undergo IMRT as in Arm I and concurrently receive docetaxel
once weekly for 6 weeks.
ARM 4: Patients undergo IMRT QD five days a week for 6 weeks and receive concurrent cisplatin
IV over 1-2 hours once weekly for 6 weeks. Starting 1 week before IMRT, patients also receive
atezolizumab IV over 30-60 minutes every 3 weeks for up to 8 doses (weeks -1, 3, 6, 9, 12,
15, 18, and 21) in the absence of disease progression and unacceptable toxicity.
After completion of study treatment, patients are followed up at 1 and 3 months, every 3
months for 2 years, every 6 months for 3 years, and then annually thereafter.
Voir cet essai sur ClinicalTrials.gov
